Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > How did we lose $5 million in cash

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jan 20, 2021 5:59pm

137 Views

Post# 32340552

RE:RE:How did we lose $5 million in cash

This is the proforma cash on hand as of the year end not as of the end of the 3rd Quarter[
quote=qwerty22]I hear Perrier Water is quite expensive.

SPCEO1 wrote: between the publishing of the corporate presentation this morning and the B. Riley presentation this afternoon? The corporate presentation says pro forma cash post the offering is $70 million while Paul mentioned $65 million on the B. Riley call. I hope they did not spend it on lunch today!

[/quote]

<< Previous

Bullboard Posts

Next >>

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions